Continuous pharmacodynamic activity of eritoran tetrasodium,a TLR4 antagonist,during intermittent intravenous infusion into normal volunteers

Abstract

Background: Eritoran tetrasodium (E5564), a structural analogue of the lipid A portion of endotoxin (lipopolysaccharide or LPS), is an antagonist of LPS and other Toll-like receptor 4 (TLR4) ligands. Eritoran tetrasodium quantitatively blocks LPS response in vivo in animal and human endotoxemia models and demonstrates a long pharmacokinetic half-life, but a short pharmacodynamic half-life. The objective of this study was to assess the safety, and pharmacokinetic and pharmacodynamic profile of E5564 infused twice-daily at three target steady-state plasma levels of approximately 1, 3 and 10 µg/ml in healthy volunteers.

Results: Loading and maintenance doses of up to 77 mg over 3 days in females and 105 mg over 6 days in males were safe and well-tolerated except for self-limiting phlebitis at the drug infusion site. Plasma levels reached steady state by 24 h. The C_max, C_min, and C₈₈, AUC_{0 —∞} were dose proportional and gender independent. Pharmacodynamic activity measured by an ex vivo LPS challenge assay, demonstrated dose-dependence for both E5564 and LPS and plasma levels of ~3 µg/ml E5564 or greater blocked up to 1 ng/ml LPS.

Conclusions: Every 12-h dosing of E5564 can replace continuous infusion, while maintaining uninterrupted blocking of high-dose LPS.

Keywords

Antagonist clinical research endotoxin Toll-like receptor-4 sepsis

References

Rossignol DP , Lynn M. Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue. J Endotoxin Res 2002; 8: 483-488.

Rossignol DP , Lynn M. TLR4 antagonists for endotoxemia and beyond . Curr Opin Invest Drugs 2005; 6: 496-502.

Rossignol DP , Christ WJ , Hawkins LD et al. Synthetic Endotoxin Antagonists. In: Brade H , Opal SM , Vogel SN , Morrison DC. (eds) Endotoxin in Health and Disease. New York: Marcel Dekker, 1999; 699-718.

Mullarkey M. , Rose JR , Bristol J. et al. Inhibition of endotoxin response by E5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J Pharmacol Exp Ther 2003; 304: 1093-1102.

Poltorak A. , He X. , Smirnova I. et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998; 282: 2085-2088.

Du X. , Poltorak A. , Silva M. , Beutler B. Analysis of TLR4-mediated LPS signal transduction in macrophages by mutational modification of the receptor. Blood Cells Mol Dis 1999; 25: 328-338.

Wong YN , Rossignol D. , Rose JR , Kao R. , Carter A. , Lynn M. Safety, pharmacokinetics and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical study. J Clin Pharmacol 2003; 43: 735-742.

Suganuma A. , Rossignol DP , Kaneko K. , LaRochelle AW , Kerns WD Clinical pharmacology of E5564, a lipid A antagonist, in a canine lipopolysaccharide challenge model. J Endotoxin Res 2000; 6: 115.

Rossignol DP , Wasan KM , Choo E. et al. Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of Eritoran (E5564) during continuous intravenous infusion into healthy volunteers. Antimicrob Agents Chemother 2004; 48: 3233-3240.

10.

Rose JR , Mullarkey MA , Christ WJ et al. Consequences of interaction of a lipophilic endotoxin antagonist with plasma lipoproteins. Antimicrob Agents Chemother 2000; 44: 504-510.

11.

Lynn M. , Wong YN , Wheeler JL et al. Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia corrected. J Pharmacol Exp Ther 2004; 308: 175-181.

12.

Lynn M. , Rossignol DP , Wheeler JL et al. Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. J Infect Dis 2003; 187: 631-639.

13.

Rose JR , Christ WJ , Bristol JR , Kawata T. , Rossignol DP Agonistic and antagonistic activities of bacterially derived Rhodobacter sphaeroides lipid A: comparison with activities of synthetic material of the proposed structure and analogs. Infect Immun 1995; 63: 833-839.

14.

Hermann C. , von Aulock S. , Dehus O. et al. Endogenous cortisol determines the circadian rhythm of lipopolysaccharide- but not lipoteichoic acid-inducible cytokine release. Eur J Immunol 2006; 36: 371-379.

15.

Akashi S. , Saitoh S. -i, Wakabayashi Y. et al. Lipopolysaccharide interaction with cell surface Toll-like receptor 4-MD-2: higher affinity than that with MD-2 or CD14. J Exp Med 2003; 198: 1035-1042.

16.

Visintin A. , Halmen KA , Latz E. , Monks BG , Golenbock DT Pharmacological inhibition of endotoxin responses is achieved by targeting the TLR4 coreceptor, MD-2. J Immunol 2005; 175: 6465-6472.

17.

Opal SM , Scannon PJ , Vincent JL et al. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis 1999; 180: 1584-1589.

18.

Northoff H. , Flegel WA , Yurttas R. , Weinstock C. The role of lipoproteins in the inactivation of endotoxin by serum. Infusionsther Transfusionsmed 1992; 19: 202-203.

19.

Hubsch AP , Casas AT , Doran JE Protective effects of reconstituted high-density lipoprotein in rabbit Gram-negative bacteremia models. J Lab Clin Med 1995; 126: 548-558.